U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07356154) titled 'A Study of Revumenib and Mezigdomide in People With Leukemia' on Jan. 20.
Brief Summary: The purpose of this study is to find out whether the combination of mezigdomide and revumenib is a safe treatment for people with relapsed or refractory KMT2A-r, NUP98-r, and NPM1-m acute leukemias.
Study Start Date: Jan. 16
Study Type: INTERVENTIONAL
Condition:
Leukemia
Acute Leukemia
Relapse Leukemia
Refractory Leukemia
Refractory Acute Leukemia
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia
Intervention:
DRUG: Revumenib
Revumenib is a novel menin inhibitor
DRUG: Mezigdomide
Mezigdomide (CC-92480) i...